Thursday, January 8, 2015

Adaptive Biotechnologies Buys Sequenta

Seattle-based Adaptive Biotechnologies said Wednesday that it has acquired Sequenta, a developer of immunosequencing products aimed at helping to diagnose and treat cancer, autoimmune disorders, and infection diseases. Financial details of the acquisition were not disclosed. Adaptive Biotechnologies said the acquisition was funded by a new, Series E financing round. No other details of that round were anounced. Adaptive Biotechnologies was advised by J.P. Morgan and DLA Piper in the deal; Sequenta was advised by Wilson Sonsini Goodrich & Rosati.